Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
US9873740B2 · kind B2 · utility
18Cited by
11References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 16, 2014 |
| Grant date | Jan 23, 2018 |
| Priority date | — |
| Expiry date | Sep 11, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.